Tocilizumab is a recombinant humanized IgG1 monoclonal antibody that reduces the pro-inflammatory effect of IL-6 and has previously been shown to reduce mortality and the need for mechanical ventilation in COVID-19 patients [12, 13]. Here, IL6 is linked to COVID-19.